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Background: There is a need for a validated short instrument that can be used in routine practice to quantify
potential short-term change in Health-Related Quality of Life (HRQoL) in patients with chronic obstructive
pulmonary disease (COPD). Our aim is to determine the validity and reliability of the VQ11 questionnaire dedicated
to the routine assessment of HRQoL.
Methods: 181 COPD patients (40–85 yrs, I to IV GOLD stages) completed the VQ11, and several tests. One week
later, 49 of these patients completed the VQ11 again.
Results: Confirmatory factor analysis supported the two-level hierarchical structure of the VQ11 with 11 items covering
three components and HRQoL at a higher level. The VQ11 showed good internal consistency and good reproducibility
(r = 0.88). Concurrent validity showed significant correlations between VQ11 total scores and St George’s Respiratory
Questionnaire-C (r = 0.70), Short Form-36 (r = −0.66 for the physical component and −0.63 for the mental component).
We obtained significant correlations with MRC Dyspnea Grades (r = 0.59), the Hospital Anxiety and
Depression Scale total score (r = 0.62), and the BODE index (r = 0.53).
Conclusion: The VQ11 has good measurement properties and provides a valid and reliable measure of
COPD-specific HRQoL. It is ready for use in routine practice.
Clinical registration: The study was approved by the University of Montpellier 1 Ethics Committee and the Regional
Ethics Committee (authorization number: A00332-53).
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Self-administered questionnaires are required in order
to estimate global outcomes of COPD [1]. Available
disease-specific Health-Related Quality of Life (HRQoL)
measures, mainly the St George’s Respiratory Question-
naire (SGRQ) [2], and the Chronic Respiratory Disease
Questionnaire (CRDQ) [3], are reliable and valid, and
widely used in clinical trials. There is increasing evi-
dence that HRQoL questionnaires can also be useful in
clinical settings [4]; however, existing instruments are* Correspondence: gregory.ninot@univ-montp1.fr
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reproduction in any medium, provided the orlengthy and have complex scoring algorithms, making
them poorly suited for routine use in clinical practice
and repeated assessment. Most patients require short
questionnaires (reducing fatigue, eliminating redundancy
of items, and facilitating spontaneous responses).
A standardized, patient-centered assessment instru-
ment covering key aspects of COPD HRQoL facilitates
information gathering and improves communication be-
tween patient and clinician, particularly for general prac-
titioners. An ideal instrument would identify specific
areas of greater severity that would serve as focal points
for targeted management or the evaluation of manage-
ment goals, thereby improving both the process and out-
come of care. The instrument must be sensitive enoughtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[6,7], valid for evaluative studies, and useful for deter-
mining rehabilitation routines. Previous studies have
shown significant changes in quality of life score be-
tween three and six months in patients with COPD
participating in a rehabilitation program [8] or, after
discharge from a rehabilitation program [9,10].
Recently, short self-administered questionnaires, the
COPD Clinical Questionnaire (CCQ) [11], the Short
Form Chronic Respiratory Disease Questionnaire (SF-
CRQ) [12], the Visual Simplified Respiratory Question-
naire (VSRQ) [13], the COPD Assessment Test (CAT)
[14], and the COPD specific HRQoL (VQ11) [15], have
been validated with similar psychometric properties
(Table 1) and some limitations.
In practice, the 8-item VSRQ and the 8-item CAT in-
clude no subscales. Conversely, the 8-item SF-CRDQ
does not provide a total score. The SF-CRDQ, VSRQ
and CAT mix answers for frequency and intensity, which
could be difficult to distinguish in patients with COPD.
Conceptually, these instruments establish confusions to
estimate the impact of COPD between health status and
HRQoL. The concept of health status refers to the impact
of health on the individual’s ability to perform daily life ac-
tivities and to benefit from them [16]. HRQoL refers to the
three broad dimensions of health: physical (e.g., autonomy,
capacity, symptoms), psychological (e.g., pain, self-esteem,
and symptoms), and social (e.g., social relationship, family
relationship) [17]. Thus, an instrument dedicated to the
measure of HRQoL needs to provide 3 dimensions
(physical, psychological and social) and an overall total score.Table 1 Psychometric properties of short HRQoL questionnair
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α Chronbach .91 .82
Test-retest .94 -
r Total SGRQ .71 -
r FEV1 -.38 -.07 to -.28Qualitatively, the SF-CRDQ and the CAT include in-
formation on daily symptoms, activity limitation and
other physical manifestations of COPD (Table 2). These
instruments are specific to the functional and psycho-
logical outcomes of COPD (symptoms, function and
confidence in living at home), whereas the social effects
produced by COPD can only be assessed by HRQoL
measures [18]. The VSRQ and the CAT do not include
any item on depression, which is prevalent in COPD pa-
tients and alters HRQoL [19]. The 10-item CCQ in-
cludes one social life question and relates directly to
respiratory problems. The VQ11 is a short instrument
that was designed to measure the functional, psycho-
logical and social aspects of COPD consequences and
provide an overall score for specific HRQoL.
Psychometrically, for all the above instruments but the
CAT and VQ11, the item reduction selection was made
by a committee of experts and without the use of statis-
tical analysis such as Confirmatory Factor Analysis. A
previous study showed that the VQ11 has good content
and internal properties [15]. This study was carried out
to verify its construct’s validity and reliability in com-
parison to other short instruments (Table 1).
Methods
Participants
Participants were recruited from three pulmonary clinics
and two medical offices between January 2008 and June
2009 using advertising flyers. To be included in the
study, patients had to be aged between 40 and 85 years,
and have an incompletely reversible limitation in airflowes for COPD patients
RQ [13] CAT [14] VQ11 [15]
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Table 2 Item coverage of short HRQoL questionnaires for
COPD patients
Dimension Aspect CCQ SF-CRDQ VSRQ CAT VQ11
Shortness of
breath
2 1 1 1 1
Fatigue 2 1 1 1
Functional Activity
limitations







Psychological Anxiety 1 2 1 1
Depression 1 1 1
Sleep 1 1 1 1
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capacity (FVC) ratio ≤ 70%) and I to IV GOLD stage
(FEV1 < 80% th.). Patients with severe or uncontrolled
comorbidities (unstable and/or uncontrolled cardiac dis-
ease, terminal disease, dementia, or an uncontrolled psy-
chiatric illness) were excluded. 181 (123 males and 58
females) participated in the study after providing in-
formed written consent. Demographic and clinical cha-
racteristics are listed in Table 3. The subjects did not
participate in any other research study during this
period. This study was approved by the University of
Montpellier 1 Ethics Committee and the Regional Ethics
Committee (authorization number: A00332-53).
Study design
Upon recruitment, the following examinations were per-
formed for each participant: a clinical assessment, the
collection of cardio-respiratory family history and
number of exacerbations for respiratory (or other) rea-
sons, a respiratory function examination (spirometry,
blood gas analysis), an electrocardiogram, and a six-
minute walk test (6MWT). Participants were also re-
quired to complete the experimental questionnaire, the
external validity questionnaires (Medical Outcome
Survey Short - SF-36, SGRQ-C, Hospitalization Anxiety
Depression Scale - HADS, Physical Self-Worth - PSW)
and a datasheet on their socio-cultural situation.
Appointments were made with participants who wereable and willing to undergo a follow-up assessment one
week later. Forty-nine participants completed the VQ11
again to test its reproducibility. To ensure uniform as-
sessments in this multicentric study (Montpellier, Paris,
Osséja), the medical and scientific committee of the
healthcare network developed recommendations and
one teaching session for a standard protocol for instru-
ment use and patient assessment.
Completion of questionnaires
The participants completed the battery of self-administered
questionnaires, presented in a randomized order, while
resting between physical tests. Participants who took part
in both sessions were examined by the same researcher
on both occasions.
VQ11
The VQ11 is a brief, self-administered HRQoL question-
naire that was specifically designed to allow individual
monitoring of COPD patients over a short-term period.
The questionnaire’s preliminary versions were developed
according to the standard stages of questionnaire vali-
dation [20,21], including evaluation of content validity,
item clarity and construct validity [15]. An initial version
of the questionnaire was drawn up by a panel of experts
consisting of 20 COPD professionals and 15 patients
with different degrees of COPD and different psycho-
social levels. The clarity of each item was then tested on
20 patients with different degrees of COPD and different
psychosocial levels. After making adjustments to the
initial questionnaire, the committee produced an experi-
mental questionnaire with 24 items, covering three
theoretical components (functional, psychological and
relational) and 11 sub-components. Each sub-compo-
nent consisted of two or three items. This experimental
questionnaire was tested on 166 COPD patients. Con-
firmatory factor analysis showed that the best model was
a two-level hierarchical model with an initial level com-
prising 11 items (one per sub-component) distributed
across three components (functional = 3 items; psycho-
logical = 4 items; social = 4 items) and a top level (lower
score indicates better HRQoL) combining these three
components. Cronbach’s alphas were calculated to test
the internal consistency scales. The resulting values were
0.83 for the functional component, 0.69 for the psycho-
logical component, 0.57 for the social component and
0.83 for the total scale. Table 4 shows the French version
of the VQ11 and a cross-cultural translation produced
by three native speakers of English.
Other questionnaires
The MOS-SF-36 [22,23], the SGRQ-C [24], the HADS
[25], and the PSW of the French version [26] of the
Physical Self-Perception Profile [27] were assessed.
Table 3 Clinical characteristics and HRQoL measures for
181 patients (123 males and 58 females)
Mean SD Min Max
Sociodemographic and overall characteristics
Age (yrs) 61.4 9.8 37 85
BMI (kg/m2) 25.7 5.4 13.1 39.7
BODE score 3.5 2.4 0 10
Dyspnea MMRC 1.4 1.3 0 3
Smoking history
Pack-years (smokers) 33.5 32.3 0.1 135.0
Pack-years (ex-smokers) 45.5 28.9 0.8 157.5
Spirometry
Pre-BD FEV1 (ml) 1395 645 460 4090
FEV1 (% pred) 49.0 20.5 15 112
FEV1/FVC (%) 47.7 12.4 25 69
Exercise tolerance
Dyspnea 6MWD end 6.0 2.1 2 10
6MWT distance (m) 470.9 122.1 90 812
6MWT distance (% pred) 70.9 17.3 14 121
HRQoL Measures
SGRQ-C Symptoms score 54.3 18.9 6.8 97.3
SGRQ-C Activity score 55.3 22.7 7.3 100.0
SGRQ-C Impact score 34.2 18.7 4.2 89.1
SGRQ-C Total score 46.3 18.5 9.7 97.7
VQ11 Functional (3–15) 8.8 2.8 3 15
VQ11 Psychological (4–20) 10.2 3.2 4 18
VQ11 Social (4–20) 9.0 3.8 4 19
VQ11 Total score (11–55) 27.9 8.8 11 49
SF-36 Physical functioning 56.3 22.8 0 100
SF-36 Role physical 40.1 35.0 0 100
SF-36 Role emotional 55.7 40.2 0 100
SF-36 Energy/vitality 46.9 18.6 0 100
SF-36 Mental Health 64.0 15.3 20 100
SF-36 Social functioning 74.4 23.4 0 100
SF-36 Bodily pain 70.2 26.7 0 100
SF-36 General health perceptions 36.2 19.9 0 95
SF-36 Physical Component Scale 50.5 22.1 8.5 96.3
SF-36 Mental Component Scale 60.3 19.0 16.0 93.5
Other Measures
HADS Anxiety score (0–21) 8.2 3.8 0 19
HADS Depression score (0–21) 6.0 3.4 0 17
HADS Total score (0–42) 14.2 6.3 1 33
Physical self-worth (1–6) 2.8 1.1 1.0 5.6
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The degree of dyspnea was measured using the Modified
Medical Research Council (MMRC) scale [28], which cor-
relates well with other scales and health status scores [29].
Analyses of respiratory function
The pulmonary function tests (PFTs) included simple
screening spirometry, formal lung volume measurement,
diffusing capacity for carbon monoxide, and arterial
blood gases. We measured the volume-time curve and
the flow-volume loop, as well as FVC and FEV1 in order
to calculate FEV1/FVC indices [30].
Exercise tolerance
The 6MWT test was performed twice with more than
30 minutes between tests in order to allow heart rate
and dyspnea to return to their initial rest values [31]. A
dyspnea score was measured on a 10-cm visual analog
scale (VAS) before and immediately after the test.
Statistical analyses
CFA was used to confirm the theoretical model found
during the internal validation (Statistical Software Mplus
5.1). Fit assessment of the CFA models was based on
multiple indicators [32-34], including the Chi-square
statistic (χ2), comparative fit index (CFI), Tucker-Lewis
Index (TLI), root mean square error of approximation
(RMSEA), and 90% confidence interval (CI) of the
RMSEA. Values greater than 0.90 for CFI and TLI are
considered to indicate adequate model fit, although
values approaching 0.95 are preferable. Values smaller
than 0.08 or 0.06 for the RMSEA indicate acceptable
and good model fit, respectively [33,34]. For the RMSEA
90% CI, values less than 0.05 for the lower bound (left
side) and less than 0.08 for the upper bound (right side)
or of 0 for the lower bound and less than 0.05 for the
upper bound (right side) indicate acceptable and good
model fit, respectively [35]. Factor loadings, squared
multiple correlations, standard errors and t values were
inspected for appropriate sign and/or magnitude.
Concurrent validity was assessed by analyzing Pearson
correlation coefficients between the dimensions of the
study questionnaire and those of another questionnaire
measuring similar concepts. Spearman correlation coeffi-
cients were calculated between the VQ11 (total and
component scores) and other independent variables. In
order to confirm good concurrent validity but no redun-
dancy, the new questionnaire had to show moderate
correlation (0.40 to 0.70) with a well-established mea-
surement tool.
Reliability is the degree to which an instrument is
free from random error. It is evaluated by measuring in-
ternal consistency reliability and reproducibility. Internal
consistency reliability refers to the homogeneity of the
Table 4 Content and structure of the VQ11 questionnaire and its cross-cultural translation by three native speakers of
English
English French
Information The following sentences express feelings about the consequences
of COPD. For each sentence, tick the intensity that best reflects
your feeling at this moment (from “not at all” to “extremely”).
There are no wrong answers. Each one is personal.
Les phrases suivantes expriment des sentiments sur les
conséquences de la BPCO. Pour chacune, cochez l’intensité qui
vous correspond le mieux maintenant (de « pas du tout » à «
extrêmement »). Aucune réponse n’est juste. Elle est avant
tout personnelle.
Dyspnea I suffer from breathlessness Je souffre de mon essoufflement
Anxiety I am worried about my respiratory condition Je me fais du souci pour mon état respiratoire
Closeness I feel my entourage (family, friends, etc.) misunderstands me Je me sens incompris(e) par mon entourage
Mobility My respiratory condition prevents me from moving about as
easily as I would like
Mon état respiratoire m’empêche de me déplacer comme je le
voudrais
Sleep I feel sleepy during the day Je suis somnolent(e) dans la journée
Life project I feel unable to achieve my objectives Je me sens incapable de réaliser mes projets
Fatigue I quickly get tired when doing day-to-day activities Je me fatigue rapidement dans les activités de la vie quotidienne
Physical
confidence
Physically, I am dissatisfied with what I can do Physiquement. je suis insatisfait(e) de ce que je peux faire
Social life My respiratory disease disrupts my social life Ma maladie respiratoire perturbe ma vie sociale
Depression I feel sad Je me sens triste
Emotional
life
My respiratory condition restricts my emotional life Mon état respiratoire limite ma vie affective
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alpha. Reproducibility establishes the stability of an in-
strument over time in a stable population and was tested
using a Pearson correlation.
Results
Patient demographics
One hundred eighty-one participants completed the study
baseline questionnaires and 49 participants completed the
follow-up questionnaires. The mean ± SD and range of the
physiological and patient-reported outcomes for the study
population are summarized in Table 3.
Factor validity
A CFA supported the validity of a two-level hierarchical
model with a three-component initial level and a single top
level (Figure 1). The weighted least squares mean- and
variance-adjusted χ2 estimator analyzed all the items as cat-
egorical variables. Fit indices were acceptable (χ2 = 133.090;
df = 24; CFI = 0.910, TLI = 0.955; RMSEA= 0.158). The fit
for the one-factor model was as good as the fit for the
three-factor model (χ2 = 135.573; df = 25; CFI = 0.909,
TLI = 0.956; RMSEA = 0.156), but it was less acceptable
with the difftest (difftest = 12.277; df: 3; p = 0.0065).
Reproducibility was assessed in terms of the correla-
tions between the measures produced by the 49 COPD
patients who were reassessed after a one-week period
(42 patients under 10% of variation; 7 patients under
20% of variation). Correlation coefficients were 0.76 for
the functional component (p < .01), 0.65 for thepsychological component (p < .01), 0.73 for the social
component (p < .01), and 0.88 for total VQ11 (p < .01).
Reliability
Cronbach’s alphas were 0.80 for the functional compo-
nent, 0.68 for the psychological component, 0.77 for the
social component and 0.89 for the whole scale. Alphas
computed using the Spearman-Brown formula were
0.91, 0.81 and 0.87, respectively.
The low correlations between VQ11 and FEV1 (func-
tional component, -0.26; total, -0.19) suggest that there
are no significant differences between groups classified
by grade of severity and VQ11 score.
Table 5 presents the clinical characteristics and
HRQoL measures of the 181 COPD participants accor-
ding to quartiles of VQ11 score. Associations between
increasing VQ11 quartiles and clinical characteristics
were found for FEV1, pre-BD FEV1, FEV1/FVC and
6MWT distance (negative association), as well as for
BODE score and dyspnea from both MMRC classifica-
tion and the 6MWT-end measure (positive association).
There were no significant associations between VQ11
quartiles and either age or BMI. HRQoL measures from
SGRQ were all positively and significantly associated
with VQ11 quartiles including SGRQ symptoms, activity,
impact and total scores (p < 0.0001).
Construct validity
The construct validity results are shown in Tables 6 and






























Figure 1 Hierarchical model and indices obtained for the VQ11 using confirmatory factor analysis (n = 181 COPD patients).
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http://www.hqlo.com/content/11/1/179scores (0.71), SF-36 component scores (−0.61 for MCS
and −0.61 for PCF), HADS total scores (0.61), and phys-
ical self-worth (−0.59). SGRQ total scores correlated
most strongly with the functional component of the
VQ11 (0.66), whereas MCS and HADS scores correlated
most strongly with the psychological and social compo-
nents of the VQ11 (−0.61 and 0.63; -0.60 and 0.61 re-
spectively). Furthermore, we found significant correla-
tions between VQ11 total scores and 6MWT end
dyspnea scores, 6MWT distances (in meters and in per-
centage of the predicted distance) and total BODETable 5 Clinical characteristics and HRQoL measures by quart
VQ11 quartiles Q1(≤20) Q2 (20–28) Q3 (2
(N = 45) (N = 51) (N
Clinical characteristics
Age (yrs) 62.1 ± 9.1* 60.9 ± 10.6 61.2
BMI (kg/m2) 25.3 ± 5.0 25.9 ± 4.7 25.0
MMRC Dyspnea 0.36 ± 0.77 1.23 ± 1.26 1.8
Pre-BD FEV1 (ml) 1676 ± 727 1413 ± 586 1176
FEV1 (% pred) 55.8 ± 18.7 51.4 ± 21.6 43.5
FEV1/FVC (%) 53.1 ± 10.3 47.5 ± 13.2 44.4
Dyspnea 6MWD end 5.2 ± 1.9 6.1 ± 1.9 5.9
6MWT distance (m) 521 ± 85.0 504 ± 119 449
BODE 1.8 ± 1.6 3.1 ± 1.9 4.2
HRQoL Measures
SGRQ-C Symptoms 43.1 ± 15.3 52.5 ± 17.1 59.1
SGRQ-C Activity 38.9 ± 17.2 51.8 ± 19.4 60.7
SGRQ-C Impact 16.3 ± 9.2 31.6 ± 13.7 42.3
SGRQ-C Total 28.9 ± 10.6 43.3 ± 13.5 53.4
*Mean ± SD.
**Significant at 0.05 level.
$Analysis of covariance for variables showing both normal distributions and homog
and/or homogeneous variance.scores (0.26, -0.37, 0.51 respectively). These correlations
were particularly satisfactory for the functional compo-
nent of the VQ11 (0.28, -0.42, 0.56 respectively). Corre-
lations with FEV1, FEV1 as a percentage of the predicted
value, FEV1/FVC and pack-years for smokers were low.
Discussion
This study examined the validity and reliability of the
VQ11, a short, self-administered questionnaire specific-
ally designed for repeated assessment of patients with
COPD and for use in routine care. The results show thatiles of VQ11 score
8–34.5) Q4 (>34.5) Scheffe** F
= 37) (N = 44) P value$
± 11.0 61.6 ± 8.1 0.94
± 5.4 26.6 ± 6.3 0.55
± 1.2 2.4 ± 1.1 Q1 < Q3; Q1 < Q2 < Q4 <0.0001
± 576 1267 ± 590 Q1 < Q3,Q4 0.002
± 19.2 44.2 ± 20.5 NS 0.013
± 11.7 45.5 ± 12.6 Q1 < Q3,Q4 0.006
± 2.1 6.7 ± 2.2 Q1 < Q4 0.026
± 111 403 ± 132 Q1,Q2 < Q4 <0.0001
± 2.2 5.2 ± 2.4 Q1,Q2 < Q4; Q1 < Q2,Q3 <0.0001
± 16.8 64.0 ± 20.0 Q1 < Q3,Q4; Q2 < Q4 <0.0001
± 18.9 71.5 ± 21.9 Q1 < Q2 < Q4; Q1 < Q3 <0.0001
± 16.8 48.9 ± 16.5 Q1 < Q2 < Q3,Q4 <0.0001
± 14.6 61.4 ± 17.0 Q1 < Q2 < Q3,Q4 <0.0001
eneous variance; Kruskal-Wallis test for variables showing normal distributions
Table 6 Correlation between VQ11 and other variables of
interest
Functional Psychological Social Total
Age 0.10 −0.11 −0.08 −0.04
BMI 0.13 0.05 0.05 0.08
Pack-years (smokers) 0.01 0.10 0.06 0.06
Pack-years (ex-smokers) 0.29 0.19 0.20 0.25
Pre-BD FEV1 −0.28 −0.14 −0.16 −0.21
FEV1 % pred −0.26 −0.14 −0.13 −0.19
FEV1/FVC −0.26 −0.17 −0.16 −0.22
MMRC Dyspnea Grade 0.61 0.49 0.51 0.59
Dyspnea 6MWD start 0.17 0.04 0.10 0.11
Dyspnea 6MWD end 0.28 0.20 0.24 0.26
Dyspnea 6MWD difference 0.17 0.19 0.16 0.19
6MWT distance (m) −0.42 −0.25 −0.34 −0.37
6MWT distance (% pred) −0.41 −0.26 −0.35 −0.38
BODE Index 0.56 0.41 0.43 0.51
In bold type, p < .05.
Table 7 Correlation between VQ11 and other
questionnaire scores
Functional Psychological Social Total
SGRQ-C
Symptoms 0.43 0.41 0.40 0.46
Activity 0.57 0.48 0.54 0.59
Impact 0.63 0.60 0.64 0.69
Total 0.66 0.61 0.65 0.71
MOS SF-36
Physical functioning −0.64 −0.50 −0.53 −0.62
Physical role −0.45 −0.38 −0.36 −0.43
Emotional role −0.28 −0.42 −0.36 −0.39
Energy/vitality −0.44 −0.56 −0.54 −0.58
Mental health −0.21 −0.46 −0.41 −0.41
Social functioning −0.40 −0.53 −0.63 −0.59
Bodily pain −0.40 −0.38 −0.46 −0.46
General health
perceptions
−0.42 −0.54 −0.51 −0.55
Physical Component
Scale
−0.52 −0.57 −0.56 −0.61
Mental Component
Scale
−0.42 −0.61 −0.60 −0.61
HADS
Anxiety 0.21 0.49 0.46 0.44
Depression 0.47 0.59 0.58 0.62
Total 0.39 0.63 0.61 0.61
Physical Self-Inventory
Physical self-worth −0.47 −0.62 −0.50 −0.59
In bold type, p < .05.
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overall COPD-related HRQoL and physical, psycho-
logical, and social components of HRQoL as expected
by experts [17].
The hierarchical structure of a preliminary version of
the VQ11 had previously been tested on a sample of 166
COPD patients [15]. Therefore, the initial aim of the
present study was to use CFA to verify this factorial
structure with a new sample of COPD patients. Our
findings demonstrated that the higher-order factor
model provided a satisfactory fit to the data and a better
fit than the alternative models. These results confirm
those from a previous study [15]. The model contains
physical, psychological, and social components, in line
with guidelines for HRQoL questionnaires [17,22,34].
Our analysis showed that these components can be ex-
amined separately.
The concurrent validity of the VQ11 was confirmed by
the correlation between VQ11 scores (for the individual
components and for the total score) and the SF-36 or
the SGRQ-C. VQ11 total scores strongly correlated with
scores for the physical and mental components of the
SF-36, and with scores on the eight scales that make up
these components. As expected, the highest correlation
was for the physical functioning scale [36]. Also as ex-
pected, the highest correlations were between corre-
sponding components of the VQ11 and the SF-36
(VQ11-functional scale and the SF-36 physical compo-
nent and physical functioning scales; VQ11-psycho-
logical scale and SF-36 emotional role, energy/vitality,
mental health, general health perceptions and mental
component scales; VQ11-social scale and SF-36 social
functioning scale). By contrast, the correlation betweenthe component and total scores on the VQ11 and the
SF-36 bodily pain scale was not particularly strong.
However, because the SF-36 was not designed to mea-
sure sleep disturbances and respiratory complaints, this
relatively weak correlation does not affect the concur-
rent validity of the VQ11. As expected, VQ11 total
scores correlated well with SGRQ-C scores and three
specific domains.
As expected also [37], VQ11 total scores correlated
well with HADS depression and total scores. The results
also supported the weak correlations between airway
obstruction and HRQoL [7,38,39].
The three components of the VQ11 are disease-specific
domains of HRQoL for COPD patients. VQ11 functional
scores correlated with dyspnea (MMRC grade and 6MWT
distance), BODE index, exercise tolerance (6MWT dis-
tance), the activity and impact scores of the SGRQ-C, and
the physical functioning and physical components of the
SF-36. The items of the VQ11 reflect the main symptoms
perceived by patients with COPD, dyspnea [28], physical
limitation [24] and fatigue [37,38,40].
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chological component of the VQ11 and the HADS an-
xiety and depression scales, the SGRQ-C impact scale,
the emotional role and mental components of the SF36,
and physical self-worth (defined as physical self-esteem).
This emphasizes that disease-associated anxiety and de-
pression are important HRQoL factors for COPD pa-
tients. The degree of anxiety felt by COPD patients has
been shown to be related to their degree of pulmonary
dysfunction [41].
The social component of VQ11 correlated with the so-
cial functioning and mental components of the SF36.
Social relationships are affected by chronic respiratory
disease, especially in patients with severe respiratory
insufficiency who often depend on close social relation-
ships to manage daily activities [42]. Patients with COPD
experience losses in several areas of their lives, and they
may feel useless, experience reduced sexual activity, de-
pend on others for their personal care and lose interest
in future projects.
The total, functional, psychological, and social compo-
nents of the VQ11 showed good reliability over a period
of one week for patients without clinical change. The
correlation coefficient for the psychological component
was the lowest. This result can be explained by intra-
individual variability in the perception of disease and
health status. A recent study noted higher day-to-day in-
stability in self-esteem, which is a major correlate factor
of HRQoL for COPD patients compared with healthy
adults [41]. Consequently, it would be advisable for clini-
cians to ask patients to complete the VQ11 every three
to six months, in order to assess the stability of patients’
perceptions of their illness, as this perception may be a
sign of vulnerability and of the likelihood they will not
fully adhere to their treatment.
There were limitations to the study. The sample was
relatively homogenous, with all subjects having moderate
to severe COPD, the majority being ex-smokers with a
significant smoking history. The concept of quality of life
and its implications on daily life are different for men and
women [21]. We could not validate the new questionnaire
separately for men and women due to the small sample
size. The VQ11 also needs to be studied in other ethnic
populations and cultures for cross-cultural validity. In
addition, the responsiveness of the VQ11 to interventions
and comparisons with other quality of life questionnaires
is also required. Last, using a new patient-reported out-
comes questionnaire requires the determination of the
minimal clinically important difference [43].
In practice, there are four general benefits to using the
VQ11: (1) It helps clinicians quickly detect the worse-
ning of HRQoL in COPD patients. This deterioration
can then be explained by the acknowledgment of COPD,
poor disease self-management (routine or acute situa-tion), the presence of comorbidities (depression, sleep
trouble, metabolic syndrome…) and/or weak support
from family and friends. Possible consequences include
an increase in the exacerbation risk and aggravation of
COPD, the development of health-risk behavior or of a
new disease, and/or the deterioration of communication
with caregivers, family or friends. (2) The three compo-
nents of the VQ11 allow caregivers to assess and correct
a number of situations: based on a high score on the
functional component, informed decisions can be made
on therapy, modification of current treatment, new as-
sessment, physiotherapy or comprehensive rehabilita-
tion; with a high score on the psychological component,
those decisions can be made regarding new assessment,
psychological support, education, or comprehensive re-
habilitation; finally, with a high score on the social
component, decisions can be made concerning social
support, psychological support, education, membership
in a health network or patients association. (3) Based on
the anticipated validation of a Minimal Clinically Im-
portant Difference, the VQ11 can also help monitor the
efficacy of an individual’s therapeutic decision. (4) Lastly,
the VQ11 provides clinicians with meaningful cues to
examine a COPD life consequence more specifically
when an answer to an item is more than three. More-
over, the back of the form includes an educational mes-
sage with a space for drawing and commenting in which
individual messages can be exchanged between patients
and caregivers, family or friends.
Conclusions
This study showed the validity and reliability of the
VQ11, a short, self-administered questionnaire specific-
ally designed for repeated assessment of patients with
COPD and for use in routine care. The VQ11 provides
clinicians and patients with a simple and reliable meas-
ure of overall COPD-related HRQoL. The VQ11 facili-
tates discussions about the overall consequences of
COPD arising from the illness’s physical symptoms and
psychological perceptions, observance behaviors, health
behaviors, life projects with COPD, and social support.
Additional information is needed to provide responsive-
ness to change at the individual patient level, an essen-
tial feature for its use in clinical practice.
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